for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atara Biotherapeutics Inc

ATRA.OQ

Latest Trade

12.49USD

Change

-0.77(-5.81%)

Volume

96,709

Today's Range

12.39

 - 

13.25

52 Week Range

11.51

 - 

43.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.26
Open
13.16
Volume
96,709
3M AVG Volume
17.58
Today's High
13.25
Today's Low
12.39
52 Week High
43.85
52 Week Low
11.51
Shares Out (MIL)
53.76
Market Cap (MIL)
712.83
Forward P/E
-2.26
Dividend (Yield %)
--

Latest Developments

More

Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS 2019

Atara Biotherapeutics Reports Q2 Loss Per Share $1.60

Atara Biotherapeutics Announces Pricing Of $150 Mln Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Industry

Biotechnology & Drugs

Contact Info

611 Gateway Blvd Ste 900

+1.650.2788930

http://www.atarabio.com/

Executive Leadership

Pascal Touchon

President, Chief Executive Officer, Director

Utpal Koppikar

Chief Financial Officer

Joseph Newell

Executive Vice President, Chief Technical Operations Officer

Mina Kim

Senior Vice President, General Counsel, Secretary

Derrell D. Porter

Senior Vice President,Head of Commercial

Key Stats

2.10 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.750

2017

-4.000

2018

-5.270

2019(E)

-5.856
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-78.16
Return on Equity (TTM)
-72.75

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up